US0197701065 - Common Stock
ALLOGENE THERAPEUTICS INC
NASDAQ:ALLO (4/19/2024, 7:00:00 PM)
After market: 3.48 +0.01 (+0.29%)3.47
+0.01 (+0.29%)
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 359 full-time employees. The company went IPO on 2018-10-11. The firm is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. The company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell-driven hematological malignancies. The company is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.
ALLOGENE THERAPEUTICS INC
210 East Grand Avenue
South San Francisco CALIFORNIA 94080
P: 16504572700
CEO: David Chang
Employees: 359
Website: https://allogene.com/
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs.
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allogene Therapeutics (NASDAQ:ALLO) just reported results for the fourth quarte...
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here you can normally see the latest stock twits on ALLO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: